These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Kiang TK; Teng XW; Karagiozov S; Surendradoss J; Chang TK; Abbott FS Toxicol Sci; 2010 Dec; 118(2):501-9. PubMed ID: 20861068 [TBL] [Abstract][Full Text] [Related]
23. Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis. Goda K; Saito K; Muta K; Kobayashi A; Saito Y; Sugai S J Toxicol Sci; 2018; 43(6):395-405. PubMed ID: 29877216 [TBL] [Abstract][Full Text] [Related]
24. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes. Porubek DJ; Grillo MP; Baillie TA Drug Metab Dispos; 1989; 17(2):123-30. PubMed ID: 2565201 [TBL] [Abstract][Full Text] [Related]
25. Enantioselective synthesis and preliminary metabolic studies of the optical isomers of 2-n-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproic acid. Porubek DJ; Barnes H; Theodore LJ; Baillie TA Chem Res Toxicol; 1988; 1(6):343-8. PubMed ID: 2979751 [TBL] [Abstract][Full Text] [Related]
26. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid. Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229 [TBL] [Abstract][Full Text] [Related]
27. Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats. Vorhees CV; Acuff-Smith KD; Weisenburger WP; Minck DR; Berry JS; Setchell KD; Nau H Teratology; 1991 Jun; 43(6):583-90. PubMed ID: 1882349 [TBL] [Abstract][Full Text] [Related]
28. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388 [TBL] [Abstract][Full Text] [Related]
29. Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid. Tang W; Palaty J; Abbott FS J Pharmacol Exp Ther; 1997 Sep; 282(3):1163-72. PubMed ID: 9316822 [TBL] [Abstract][Full Text] [Related]
30. Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Bjorge SM; Baillie TA Drug Metab Dispos; 1991; 19(4):823-9. PubMed ID: 1680661 [TBL] [Abstract][Full Text] [Related]
31. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383 [TBL] [Abstract][Full Text] [Related]
32. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Tong V; Teng XW; Chang TK; Abbott FS Toxicol Sci; 2005 Aug; 86(2):436-43. PubMed ID: 15858222 [TBL] [Abstract][Full Text] [Related]
33. Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility. El-Mowafy AM; Abdel-Dayem MA; Abdel-Aziz A; El-Azab MF; Said SA Biochim Biophys Acta; 2011; 1811(7-8):460-7. PubMed ID: 21571092 [TBL] [Abstract][Full Text] [Related]
34. Trans-2-ene-valproic acid is less behaviorally teratogenic than an equivalent dose of valproic acid in rats. Fisher JE; Acuff-Smith KD; Schilling MA; Nau H; Vorhees CV Teratology; 1994 Jun; 49(6):479-86. PubMed ID: 7747269 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat. Singh K; Orr JM; Abbott FS Drug Metab Dispos; 1988; 16(6):848-52. PubMed ID: 2907464 [TBL] [Abstract][Full Text] [Related]
36. Toxicity of valproic acid in isolated rat liver mitochondria. Jafarian I; Eskandari MR; Mashayekhi V; Ahadpour M; Hosseini MJ Toxicol Mech Methods; 2013 Oct; 23(8):617-23. PubMed ID: 23819490 [TBL] [Abstract][Full Text] [Related]
37. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993 [TBL] [Abstract][Full Text] [Related]
38. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Lee MH; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO Toxicol Appl Pharmacol; 2008 Feb; 226(3):271-84. PubMed ID: 17963808 [TBL] [Abstract][Full Text] [Related]
39. Capillary GCMS assay of 2-n-propyl-4-pentenoic acid (4-ene VPA) in rat plasma and urine. Singh K; Abbott FS; Orr JM Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):211-23. PubMed ID: 3602586 [TBL] [Abstract][Full Text] [Related]
40. Reversal of the adverse chronic effects of the unsaturated derivative of valproic acid--2-n-propyl-4-pentenoic acid--on ketogenesis and liver coenzyme A metabolism by a single injection of pantothenate, carnitine, and acetylcysteine in developing mice. Thurston JH; Hauhart RE Pediatr Res; 1993 Jan; 33(1):72-6. PubMed ID: 8433865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]